NCT00451048 · REGISTRY CONDITION SEARCH

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2018-09-04

This phase II trial is studying how well sunitinib works in treating patients with myelodysplastic syndromes or chronic myelomonocytic leukemia. Sunitinib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria

→

outcome · POSTED

Number Participants With Complete, Partial or Hematologic Improvement Response

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

Time to Progression

→

outcome · POSTED

Highest Severity of Observed Adverse Events Assessed by Common Terminology Criteria or Adverse Events Version 3.0 (CTCAE v3.0)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * MDS syndromes meeting 1 of the following: Intermediate-2 disease, high-risk disease (IPSS score\>=1.5) * CMML: WBC\>12,000/mm\^3, Intermediate-2 disease with WBC=\<12,000/mm\^3, high-risk disease (IPSS score\>=1.5) with WBC=\<12,000/mm\^3 * Patients with insufficient/inadequate metaphases for cytogenetic analysis are eligible if bone marrow blasts are \>10% and/or 2-3 cytopenias are present * No known brain metastases * Life expectancy\>12 weeks * ECOG PS 0-2/Karnofsky PS 60-100% * Calcium=\<3.0 mmol/L * Bilirubin normal * AST and ALT=\<2.5 times upper limit of normal * Creatinine normal/creatinine clearance\>=60 mL/min Exclusion Criteria: * No history of significant ECG abnormalities including but not limited to: ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation\>=3 beats in a row); QTc prolongation (i.e.QTc interval\>=500msec) * No history of allergic reaction to compounds of similar chemical/biological composition to sunitinib malate * No NYHA class III-IV congestive heart failure * Patients with history of NYHA class II congestive heart failure who are asymptomatic on treatment are eligible * No abdominal fistula/G perforation/intraabdominal abscess within past 28 days * No serious cardiovascular disease within past 12 months including: cerebrovascular accident or transient ischemic attack, myocardial infarction, cardiac arrhythmia, stable or unstable angina, symptomatic congestive heart failure, coronary or peripheral artery bypass graft or stenting * No pulmonary embolism within past 12 months * No uncontrolled hypertension (systolic BP\>=140 mmHg/diastolic BP\>=90 mmHg) * No condition impairing ability to swallow/retain sunitinib malate tablets including: GI tract disease resulting in inability to take oral medication, requirement for IV alimentation, prior surgical procedures affecting absorption, active peptic ulcer disease * No serious/nonhealing wound, ulcer, or bone fracture * No uncontrolled pre-existing thyroid abnormality * No concurrent uncontrolled illness including ongoing/active infection * No psychiatric illness/social situation that would preclude study participation * Not pregnant/nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception * 4 weeks since prior major surgery * Prior central thoracic radiotherapy that included heart in radiotherapy port allowed provided NYHA congestive heart failure=\<class II * Prior anthracycline exposure allowed provided NYHA congestive heart failure=\<class II * No other prior therapy for MDS/CMML except epoetin alfa, darbepoetin alfa, filgrastim or sargramostim * At least 2 weeks since prior epoetin alfa * At least 4 weeks since prior darbepoetin alfa * No other prior antiangiogenic agents including but not limited to: bevacizumab, sorafenib tosylate, pazopanib hydrochloride, AZD2171, vatalanib, VEGF Trap * More than 7 days since prior and no concurrent potent CYP3A4 inhibitors * More than 12 days since prior and no concurrent potent CYP3A4 inducers including: Rifampin, Rifabutin, Carbamazepine, Phenobarbital, Phenytoin, Hypericum perforatum, Efavirenz, Tipranavir * No concurrent birth control patch/oral birth control pills/depot/injectable birth control methods * No concurrent therapeutic coumarin-derivative anticoagulants * Low dose(=\<2mg) warfarin for prophylaxis of thrombosis allowed * Low molecular weight heparin allowed if INR=\<1.5 * No concurrent agents with proarrhythmic potential including: Terfenadine, Quinidine, Procainamide, Disopyramide, Sotalol, Probucol, Bepridil, Haloperidol, Risperidone, Indapamide, Flecainide acetate * No concurrent combination antiretroviral therapy for HIV-positive patients * No other concurrent investigational agents
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients will receive sunitinib malate (SU11248) by mouth once a day. Treatment may continue for as long as benefit is shown.
intervention Names
Drug: sunitinib malate
label
Arm I
type
EXPERIMENTAL

interventions

arm Group Labels
Arm I
description
Given orally
name
sunitinib malate
other Names
SU11248
sunitinib
Sutent
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 10
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

measure
Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria
time Frame
Up to 6 years

secondary Outcomes

description
Assessed by achievement of Complete Response (CR), Partial Response (PR) or Hematologic Improvement (HI)
measure
Number Participants With Complete, Partial or Hematologic Improvement Response
time Frame
Up to 6 years
measure
Overall Survival
time Frame
At 6 months and 1 year
measure
Progression-free Survival
time Frame
At 6 months and 1 year
measure
Time to Progression
time Frame
At 6 months and 1 year
measure
Highest Severity of Observed Adverse Events Assessed by Common Terminology Criteria or Adverse Events Version 3.0 (CTCAE v3.0)
time Frame
Up to 6 years

Full study description

brief Summary: This phase II trial is studying how well sunitinib works in treating patients with myelodysplastic syndromes or chronic myelomonocytic leukemia. Sunitinib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth.
detailed Description: OBJECTIVES: I. Determine the overall response rate (complete response, partial response, or hematological improvement) in patients with intermediate-2 or high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia treated with sunitinib malate. II. Determine the duration of response in patients treated with this drug. III. Determine the overall survival of patients treated with this drug. IV. Determine the progression-free survival of patients treated with this drug. V. Determine the time to disease progression in patients treated with this drug. VI. Determine the toxicity of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 3-4 weeks and then monthly thereafter.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-c13d08e40485a1775c7e
requested nct id
NCT00451048
primary nct id
NCT00451048
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Juvenile+Myelomonocytic+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
payload sha256
e92c4d4b435769e5782b1548b83d085fd28e03361c01d55bebd154ad30980ae6
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-c13d08e40485a1775c7e
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00451048
occurrences
context exact
NCT00451048
end
11
exact text
NCT00451048
start
0
offset unit
unicode_code_points
query cond
Juvenile Myelomonocytic Leukemia
query disease state id
ds-juvenile-myelomonocytic-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
source file sha256
cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
source json pointer
/studies/119/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d4275d0172a74d120f65707cfe3a24420e2fbcd6fe4035388da67020c7990bf7
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Juvenile+Myelomonocytic+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice